Amylyx Pharmaceuticals (NASDAQ: AMLX) revenue
Amylyx Pharmaceuticals reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($87.4m).
Amylyx Pharmaceuticals's revenue has fallen for 2 years in a row, and its best year of the last 5 was fiscal 2023. The biggest drop was in fiscal 2024, −77.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | −100.0% | −$153.3m | — |
| 2024 | $87.4m | −77.1% | −$314.7m | −360.2% |
| 2023 | $380.8m | +1,612.9% | $38.8m | 10.2% |
| 2022 | $22.2m | +7,700.0% | −$201.3m | −905.7% |
| 2021 | $0.3m | — | −$82.7m | −29,013.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Amylyx Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Amylyx Pharmaceuticals ranks 403rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Amylyx Pharmaceuticals, −100.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 401st | Altimmune | $0.0m | 105.0% |
| 402nd | Lyell Immunopharma | $0.0m | −41.0% |
| 403rd | Amylyx Pharmaceuticals | $0.0m | −100.0% |
| 404th | Artiva Biotherapeutics | $0.0m | −100.0% |
| 405th | Capricor Therapeutics | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Amylyx Pharmaceuticals
- How much revenue did Amylyx Pharmaceuticals make in fiscal 2025?
- Amylyx Pharmaceuticals reported revenue of $0.0m for fiscal 2025, compared with $87.4m in fiscal 2024.
- What was the best year for revenue at Amylyx Pharmaceuticals?
- Of its last 5 fiscal years, fiscal 2023, with $380.8m.
- Where does Amylyx Pharmaceuticals rank in its sector by revenue?
- It ranks 403rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Amylyx Pharmaceuticals come from?
- From the annual report (Form 10-K) that Amylyx Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Amylyx Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Amylyx Pharmaceuticals: the Amylyx Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.